| Literature DB >> 33110208 |
Jonathan Briones1, Wilfred Espulgar1, Shohei Koyama2, Hyota Takamatsu2, Eiichi Tamiya3,4, Masato Saito5,6.
Abstract
Recent advances in microfluidic techniques have enabled researchers to study sensitivities to immune checkpoint therapy, to determine patients' response to particular antibody treatment. Utilization of this technology is helpful in antibody discovery and in the design of personalized medicine. A variety of microfluidic approaches can provide several functions in processes such as immunologic, genomic, and/or transcriptomic analysis with the aim of improving the efficacy and coverage of immunotherapy, particularly immune checkpoint blockade (ICB). To achieve this requires researchers to overcome the challenges in the current state of the technology. This review looks into the advancements in microfluidic technologies applied to researches on immune checkpoint blockade treatment and its potential shift from proof-of-principle stage to clinical application.Entities:
Mesh：
Substances：
Year: 2020 PMID： 33110208 DOI： 10.1038/s41417-020-00248-7
Source DB: PubMed Journal: Cancer Gene Ther ISSN： 0929-1903 Impact factor: 5.987